FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert

Find Clinical Drug Pipeline Developments & Deals by BioIntervene


All Data

Filters Filter refresh
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BIO-205

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: MPM Capital

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 07, 2020


            The financing will be used to advance the company’s lead program, BIO-205, through human proof-of-concept studies in neuropathic pain as well as to advance its portfolio of A3AR agonists.